查看文章

Objective:

To assess the cardiovascular safety of two commonly prescribed atypical antipsychotics risperidone (RSP) and olanzapine (OZP) in schizophrenic patients, using electrocardiography (ECG) and Blood Pressure (BP).

Materials and Methods:

This was a 10-week prospective open label, observational study, carried out in a newly diagnosed 64 schizophrenic patients receiving either RSP or OZP. RSP (n= 32) was started with dose of 2 mg/day and increased to 4 mg/day after 2 weeks, whereas OZP (n= 32) was started at a dose of 5 mg/day and was increased to 10 mg/day after 2 weeks. Heart rate (HR), ECG parameters (PR, RR, QRS, QT intervals and QTc and QTd) and BP (systolic and diastolic in supine and standing position) were recorded at baseline (before drug therapy)) and during follow-up visits at 2 (I), 6 (II) and 10 (III) weeks.

Results:

In the RSP group, at II and III follow-ups, a significant increase in the …